|
|
 Previous Article | Table of Contents | Next Article 
Blood, 1 September 2000, Vol. 96, No. 5, pp. 1900-1905
NEOPLASIA
Effective targeting of tumor vasculature by the angiogenesis
inhibitors vasostatin and interleukin-12
Lei Yao,
Sandra E. Pike,
Joyce Setsuda,
Justin Parekh,
Ghanshyam Gupta,
Mark Raffeld,
Elaine S. Jaffe, and
Giovanna Tosato
From the Medicine Branch, National Cancer Institute,
Division of Clinical Sciences, National Institutes of Health, Bethesda,
MD; Center for Biologics Evaluation and Research, Rockville, MD; and
Laboratory of Pathology, National Cancer Institute, Division of
Clinical Science, National Institutes of Health, Bethesda, MD.
Solid tumors are dependent on preexisting vasculature and
neovascularization for their growth. Successful cancer therapies targeting the tumor vasculature would be expected to block the existing
tumor blood supply and to prevent tumor neovascularization. We tested
the antitumor activity of experimental therapy with 2 distinct
antiangiogenic drugs. Vasostatin inhibits endothelial cell growth and
neovascularization, and interleukin-12 (IL-12) targets the tumor
vasculature acting through interferon- (IFN-) and the downstream
chemokines interferon-inducible protein-10 (IP-10) and monokine induced
by IFN-. Individually, vasostatin and IL-12 produced distinct
efficacy profiles in trials aimed at reducing tumor growth in athymic
mice. In combination, these inhibitors halted the growth of human
Burkitt lymphoma, colon carcinoma, and ovarian carcinoma. Thus, cancer
therapy that combines distinct inhibitors of angiogenesis is a novel,
effective strategy for the experimental treatment of cancer.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
A. Zipin-Roitman, T. Meshel, O. Sagi-Assif, B. Shalmon, C. Avivi, R. M. Pfeffer, I. P. Witz, and A. Ben-Baruch
CXCL10 Promotes Invasion-Related Properties in Human Colorectal Carcinoma Cells
Cancer Res.,
April 1, 2007;
67(7):
3396 - 3405.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Pal, J. Wu, J. K. Murray, S. H. Gellman, M. A. Wozniak, P. J. Keely, M. E. Boyer, T. M. Gomez, S. M. Hasso, J. F. Fallon, et al.
An antiangiogenic neurokinin-B/thromboxane A2 regulatory axis
J. Cell Biol.,
September 25, 2006;
174(7):
1047 - 1058.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. K. Hong, P. Kumar, L. Wang, B. Damania, M. L. Gulley, H.-J. Delecluse, P. J. Polverini, and S. C. Kenney
Epstein-Barr Virus Lytic Infection Is Required for Efficient Production of the Angiogenesis Factor Vascular Endothelial Growth Factor in Lymphoblastoid Cell Lines
J. Virol.,
November 15, 2005;
79(22):
13984 - 13992.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Nyberg, L. Xie, and R. Kalluri
Endogenous Inhibitors of Angiogenesis
Cancer Res.,
May 15, 2005;
65(10):
3967 - 3979.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. Vucenik, A. Passaniti, M. I. Vitolo, K. Tantivejkul, P. Eggleton, and A. M. Shamsuddin
Anti-angiogenic activity of inositol hexaphosphate (IP6)
Carcinogenesis,
November 1, 2004;
25(11):
2115 - 2123.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. L. Rakhmilevich, A. T. Hooper, D. J. Hicklin, and P. M. Sondel
Treatment of experimental breast cancer using interleukin-12 gene therapy combined with anti-vascular endothelial growth factor receptor-2 antibody
Mol. Cancer Ther.,
August 1, 2004;
3(8):
969 - 976.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Murga, L. Yao, and G. Tosato
Derivation of Endothelial Cells from CD34- Umbilical Cord Blood
Stem Cells,
May 1, 2004;
22(3):
385 - 395.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. TOSETTI, N. FERRARI, S. DE FLORA, and A. ALBINI
Angioprevention': angiogenesis is a common and key target for cancer chemopreventive agents
FASEB J,
January 1, 2002;
16(1):
2 - 14.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. S. Marchand, N. Noiseux, J.-F. Tanguay, and M. G. Sirois
Blockade of in vivo VEGF-mediated angiogenesis by antisense gene therapy: role of Flk-1 and Flt-1 receptors
Am J Physiol Heart Circ Physiol,
January 1, 2002;
282(1):
H194 - H204.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. S. Kerbel
Clinical Trials of Antiangiogenic Drugs: Opportunities, Problems, and Assessment of Initial Results
J. Clin. Oncol.,
September 15, 2001;
19(90001):
45s - 51.
[Full Text]
[PDF]
|
|
|
|
|
